Canaccord Genuity Reiterates a 'Buy' on Anthera Pharma (ANTH); Expectations for June Phase 2 PEARL Trial
Tweet
Share
E-mailGet Alerts ANTH Hot Sheet
Price: $0.00 --0%
Rating Summary:
8 Buy, 3 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 17 | New: 16
Rating Summary:
8 Buy, 3 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 17 | New: 16
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Anthera Pharma (NASDAQ: ANTH) price target of $6.00.
Analyst, Ritu Baral, said, "Reiterate rating and price target on blisibimod (B--mod) clinical and commercial potential in lupus. We expect B-mod, ANTH’s BAFF peptibody for lupus, will yield positive data from the Phase 2 PEARL trial in June and ANTH to start the Phase 3 Chablis trial in Q1/13. ANTH may start Phase 2 B-mod trials in other lupus-related B cell disorders to leverage market potential and diversify clinical risk."
For an analyst ratings summary and ratings history on Anthera Pharma click here. For more ratings news on Anthera Pharma click here.
Shares of Anthera Pharma closed at $2.32 yesterday.
Analyst, Ritu Baral, said, "Reiterate rating and price target on blisibimod (B--mod) clinical and commercial potential in lupus. We expect B-mod, ANTH’s BAFF peptibody for lupus, will yield positive data from the Phase 2 PEARL trial in June and ANTH to start the Phase 3 Chablis trial in Q1/13. ANTH may start Phase 2 B-mod trials in other lupus-related B cell disorders to leverage market potential and diversify clinical risk."
For an analyst ratings summary and ratings history on Anthera Pharma click here. For more ratings news on Anthera Pharma click here.
Shares of Anthera Pharma closed at $2.32 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HSBC Downgrades Feng Tay Enterprises (9910:TT) to Hold
- B.Riley Resumes Magnite (MGNI) at Buy
- B.Riley Resumes EverQuote (EVER) at Buy
Create E-mail Alert Related Categories
Analyst Comments, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
